Payment overview · 2025
General Payments
$2,997.12
115 reported records · 27 companies
Healthcare provider profile · identity verified
Steven Harry Barag, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · RANCHO CUCAMONGA, CA · NPI 1366444838
Verified facts
What the public records show
CMS Open Payments records show Steven Harry Barag, D.O. received $2,997.12 in general payments during 2025 across 115 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Edarbi, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Nexletol, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Edarbyclor by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $738.83 | 24.6% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $308.28 | 10.3% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $293.13 | 9.8% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $211.40 | 7.0% | 8 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $193.73 | 6.5% | 11 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $163.53 | 5.5% | 9 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $147.61 | 4.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.00 | 4.0% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $120.32 | 4.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $103.43 | 3.5% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $85.99 | 2.9% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $64.51 | 2.1% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $58.69 | 2.0% | 3 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $52.92 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.47 | 1.6% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $41.09 | 1.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.30 | 1.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $29.46 | 1.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.61 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.03 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.07 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.45 | 0.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.15 | 0.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.06 | 0.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.75 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.81 | 0.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.50 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,964.85 | 114 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $420.63 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $259.97 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $211.40 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.07 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $193.73 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $177.48 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $163.53 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $158.07 | 10 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $147.61 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $121.00 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $120.32 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $119.26 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $87.28 | 6 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $85.99 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $64.51 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $64.51 | 3 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $64.51 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $63.94 | 5 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $63.57 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $58.69 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.79 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $52.92 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.55 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $41.09 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.30 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $29.46 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.14 | 1 | 2025 |
Source payment records
|
|||||
| RECOMBIVAX HB Normalized: recombivax hb |
Biological | Merck Sharp & Dohme LLC | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| NEXLIZET Normalized: nexlizet |
Drug | Esperion Therapeutics, Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| EDARBI edarbi |
2025 | Edarbi | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 161 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 62 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 262 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 50 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 33 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 203 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 75 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
161 | 53 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
262 | 66 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
262 | 66 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
203 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
75 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 683 | 193 |
| Losartan Potassium | Losartan Potassium | 473 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 426 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 345 | 91 |
| Metformin Hcl | Metformin Hcl | 287 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 281 | 85 |
| Omeprazole | Omeprazole | 268 | 79 |
| Jardiance | Empagliflozin | 262 | 66 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 208 | 61 |
| Mounjaro | Tirzepatide | 203 | 42 |
| Trazodone Hcl | Trazodone Hcl | 193 | 64 |
| Simvastatin | Simvastatin | 189 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 63 |
| Azithromycin | Azithromycin | 178 | 147 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 174 | 45 |
| Gabapentin | Gabapentin | 173 | 61 |
| Farxiga | Dapagliflozin Propanediol | 161 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 47 |
| Lisinopril | Lisinopril | 143 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 38 |
| Finasteride | Finasteride | 138 | 44 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 132 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 46 |
| Ozempic | Semaglutide | 129 | 27 |
| Meloxicam | Meloxicam | 128 | 43 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 127 | 111 |
| Ibuprofen | Ibuprofen | 124 | 43 |
| Carvedilol | Carvedilol | 114 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 35 |
| Montelukast Sodium | Montelukast Sodium | 103 | 33 |
| Furosemide | Furosemide | 102 | 30 |
| Allopurinol | Allopurinol | 100 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 31 |
| Potassium Chloride | Potassium Chloride | 96 | 29 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 95 | 28 |
| Ezetimibe | Ezetimibe | 94 | 29 |
| Atenolol | Atenolol | 90 | 23 |
| Famotidine | Famotidine | 88 | 24 |
| Eliquis | Apixaban | 84 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 76 | 15 |
| Buspirone Hcl | Buspirone Hcl | 75 | 28 |
| Chlorthalidone | Chlorthalidone | 75 | 19 |
| Rybelsus | Semaglutide | 75 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 54 |
| Gemtesa | Vibegron | 62 | 15 |
| Januvia | Sitagliptin Phosphate | 59 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 19 |
| Azelastine Hcl | Azelastine Hcl | 55 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 16 |
| Valsartan | Valsartan | 53 | suppressed |
| Kerendia | Finerenone | 50 | 14 |
| Sertraline Hcl | Sertraline Hcl | 50 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 18 |
| Edarbi | Azilsartan Medoxomil | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 16 |
| Metformin Hcl Er | Metformin Hcl | 42 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Meclizine Hcl | Meclizine Hcl | 38 | 20 |
| Methocarbamol | Methocarbamol | 37 | 11 |
| Tramadol Hcl | Tramadol Hcl | 37 | 23 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 11 |
| Baclofen | Baclofen | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 16 |
| Methylprednisolone | Methylprednisolone | 35 | 34 |
| Vascepa | Icosapent Ethyl | 35 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Linzess | Linaclotide | 33 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 19 |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 30 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | 18 |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 19 |
| Nexletol | Bempedoic Acid | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | 13 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cialis | Tadalafil | 13 | suppressed |
| Dapsone | Dapsone | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,997.12 · 115 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, CONTRAVE, CREON, Cologuard Collection Kit, EDARBI, FARXIGA, GARDASIL 9, GEMTESA, General - Pain Management, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LINZESS, M-M-R II, MOUNJARO, NEMLUVIO, NEXLETOL, NEXLIZET, NURTEC ODT, Ozempic, PROCLAIM, QULIPTA, RECOMBIVAX HB, Rybelsus, Symbravo, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VAQTA, VOQUEZNA, VRAYLAR, VYNDAQEL, Veozah, Wegovy, XIFAXAN, XYOSTED, Xhance, ZAVZPRET, ZEPBOUND, ZORYVE | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error